<DOC>
	<DOCNO>NCT03052764</DOCNO>
	<brief_summary>This study evaluate efficacy safety onabotulinumtoxinA 100 U ( BOTOX® ) , compare placebo , inject bladder use alternative injection paradigm reduce number daily urinary incontinence episode patient overactive bladder ( OAB ) urinary incontinence whose symptom adequately manage anticholinergic .</brief_summary>
	<brief_title>Evaluation Alternative Injection Paradigm OnabotulinumtoxinA ( BOTOX® ) Treatment Overactive Bladder Patients With Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Participant weigh ≥ 40 kg ( 88 lb ) Participant symptom Over Active Bladder ( OAB ) ( frequency urgency ) urinary incontinence period least 6 month immediately prior screening . Participant symptoms OAB due know neurological reason ( eg , spinal cord injury , multiple sclerosis , cerebrovascular accident , Alzheimer 's disease , Parkinson 's disease , etc . ) Participant receive pharmacologic therapy treat symptom OAB , include nocturia , within 7 day start screen period procedure Participant use clean intermittent catheterization ( CIC ) indwell catheter manage urinary incontinence Participant treat intravesical pharmacologic agent ( eg , capsaicin , resiniferatoxin ) within 12 month Day 1 Participant previous current botulinum toxin therapy serotype urological condition Participant previous current botulinum toxin therapy serotype nonurological condition within 12 week Day 1 Participant immunize botulinum toxin serotype Participant history evidence pelvic urological abnormality , bladder surgery disease , OAB , may affect bladder function Participant active genital infection , genital wart , either concurrently within 4 week prior screen Participant history current diagnosis bladder cancer urothelial malignancy Participant male previous current diagnosis prostate cancer Participant history 2 urinary tract infection ( UTIs ) within 6 month Day 1 take prophylactic antibiotic prevent chronic UTIs Participant current previous uninvestigated hematuria Participant hemophilia , clot factor deficiency , disorder cause bleed diathesis Participant withhold antiplatelet , anticoagulant therapy medication anticoagulant effect 3 day prior Day 1 Participant know allergy sensitivity botulinum toxin preparation Participant medical condition may put him/her increase risk exposure BOTOX® include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis Participant current swallow breathing difficulty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>